Sarepta Therapeutics (SRPT) Gets a Buy from Oppenheimer

In a report released today, Andreas Argyrides from Oppenheimer maintained a Buy rating on Sarepta Therapeutics, with a price target of $37.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Argyrides covers the Healthcare sector, focusing on stocks such as Evommune, Inc., Tarsus Pharmaceuticals, and MoonLake Immunotherapeutics. According to TipRanks, Argyrides has an average return of 10.3% and a 43.17% success rate on recommended stocks.

In addition to Oppenheimer, Sarepta Therapeutics also received a Buy from Mizuho Securities’s Uy Ear in a report issued today. However, on the same day, William Blair reiterated a Hold rating on Sarepta Therapeutics (NASDAQ: SRPT).

Based on Sarepta Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $399.36 million and a GAAP net loss of $179.95 million. In comparison, last year the company earned a revenue of $467.17 million and had a net profit of $33.61 million

Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRPT in relation to earlier this year. Most recently, in December 2025, Ian Michael Estepan, the COO of SRPT sold 13,187.00 shares for a total of $294,201.97.